Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)

Blood

Volumn 100, Issue 3, 2002, Pages 768-773

  Lundin, Jeanette ^a,b   Kimby, Eva ^a,b   Björkholm, Magnus ^a,b   Broliden, Per Anders ^a,b   Celsing, Fredrik ^a,b   Hjalmar, Viktoria ^a,b   Möllgård, Lars ^a,b   Rebello, Peppy ^a,b   Hale, Geoff ^a,b   Waldmann, Herman ^a,b   Mellstedt, Håkan ^a,b   Österborg, Anders ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Therapeutic Antibody Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALLOPURINOL; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; CD52 ANTIGEN; CLEMASTINE; COTRIMOXAZOLE; FLUCONAZOLE; GANCICLOVIR; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN MONOCLONAL ANTIBODY; PARACETAMOL; VALACICLOVIR;

ADULT; ARTICLE; B CELL LEUKEMIA; BONE MARROW TOXICITY; CANCER IMMUNOTHERAPY; CHRONIC LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; HUMAN; HYPERURICEMIA; INFECTIOUS COMPLICATION; INJECTION SITE; NEUTROPENIA; PAIN; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RASH; TREATMENT OUTCOME;

EID: 0036683449     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-01-0159     Document Type: Article

References (27)

1. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia
2. Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective, randomized, multicenter trial
3. Reshaping human antibodies for therapy
4. Variability in B-cell antigen expression: Implications for the treatment of B-cell lymphomas and leukemias with monoclonal antibodies
5. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro
6. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
7. Structural motifs involved in human IgG antibody effector functions
8. Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation
9. Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells
10. Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H
11. Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma
12. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: A phase II multicenter study
13. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia
14. Multicenter study of Campath-1H in patients with chronic lymphocytic leukemia (B-CLL) refractory to fludarabine
15. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia
16. Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia
17. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatment
18. Manufacture and quality control of CAMPATH-1 antibodies for clinical trials
19. Clinical staging of chronic lymphocytic leukemia
20. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia
21. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
22. Rituximab as first-line and maintenance therapy for patients with small lymphocytic lymphoma (SLL) and chronic lymphocytic leukemia (CLL)
23. Pharmacokinetics of CAMPATH-1H: Assay development and validation
24. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program
25. Campath-1H in B-chronic lymphocytic leukemia: Report on a patient treated thrice in a 3-year period
26. Phase II study of alemtuzumab in patients with advanced mycosis fungoides/Sezary syndrome
27. Campath-1H in CLL: Immune reconstitution and viral infections during and after therapy